In one paragraphArticle in Protein & cell, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
19 authors.
Brian C LinDivision of Hemostasis, Office of Therapeutic Products, Center for Biologics Evaluation and Research, US FDA, Silver Spring, MD, 20993, United States.ORCID 0000-0003-2944-3051 Katarzyna I JankowskaDivision of Hemostasis, Office of Therapeutic Products, Center for Biologics Evaluation and Research, US FDA, Silver Spring, MD, 20993, United States.ORCID 0000-0002-2219-2096 Upendra K KatneniDivision of Hemostasis, Office of Therapeutic Products, Center for Biologics Evaluation and Research, US FDA, Silver Spring, MD, 20993, United States.ORCID 0000-0002-8145-8894 Randilu AmarasingheDivision of Hemostasis, Office of Therapeutic Products, Center for Biologics Evaluation and Research, US FDA, Silver Spring, MD, 20993, United States.ORCID 0009-0005-5181-309X Nigam PadhiarDivision of Hemostasis, Office of Therapeutic Products, Center for Biologics Evaluation and Research, US FDA, Silver Spring, MD, 20993, United States.ORCID 0000-0001-7087-9979 Nobuko Hamasaki-KatagiriDivision of Hemostasis, Office of Therapeutic Products, Center for Biologics Evaluation and Research, US FDA, Silver Spring, MD, 20993, United States.ORCID 0000-0003-4954-9435 Wells W WuFacility for Biotechnology Resources, Center for Biologics Evaluation and Research, US FDA, Silver Spring, MD, 20993, United States.ORCID 0000-0002-6392-2235 Haojie ZhuCell Biology Center, Institute of Innovative Research, Tokyo Institute of Technology, Yokohama, 226-8503, Japan.
Hideki TaguchiCell Biology Center, Institute of Innovative Research, Tokyo Institute of Technology, Yokohama, 226-8503, Japan.ORCID 0000-0002-6612-9339 Arnab GhoshCenter for Gene Regulation in Health and Disease and the Department of Biological, Geological and Environmental Sciences, Cleveland State University, Cleveland, OH, 44115, United States.ORCID 0000-0003-1952-1044 David D HolcombDivision of Hemostasis, Office of Therapeutic Products, Center for Biologics Evaluation and Research, US FDA, Silver Spring, MD, 20993, United States.ORCID 0000-0002-4712-7952 Je-Nie PhueFacility for Biotechnology Resources, Center for Biologics Evaluation and Research, US FDA, Silver Spring, MD, 20993, United States.ORCID 0000-0002-3502-3726 Sarah E FumagalliDivision of Hemostasis, Office of Therapeutic Products, Center for Biologics Evaluation and Research, US FDA, Silver Spring, MD, 20993, United States.ORCID 0000-0003-2469-4476 Darón I FreedbergLaboratory of Bacterial Polysaccharides, Division of Bacterial, Parasitic, and Allergenic Products, Center for Biologics Evaluation and Research, US FDA, Silver Spring, MD, 20993, United States.ORCID 0000-0003-1991-5174 Ofer KimchiCenter for the Physics of Biological Function, Princeton University, Princeton, NJ, 08544, United States.ORCID 0000-0002-0801-0727 Rong-Fong ShenFacility for Biotechnology Resources, Center for Biologics Evaluation and Research, US FDA, Silver Spring, MD, 20993, United States.
Anton A KomarCenter for Gene Regulation in Health and Disease and the Department of Biological, Geological and Environmental Sciences, Cleveland State University, Cleveland, OH, 44115, United States.ORCID 0000-0003-4188-0633 Zuben E SaunaDivision of Hemostasis, Office of Therapeutic Products, Center for Biologics Evaluation and Research, US FDA, Silver Spring, MD, 20993, United States.ORCID 0000-0001-8202-5188 Chava Kimchi-SarfatyDivision of Hemostasis, Office of Therapeutic Products, Center for Biologics Evaluation and Research, US FDA, Silver Spring, MD, 20993, United States.ORCID 0000-0002-9355-8585 Funding
Safer and more effective FIX therapeutics: impact of codon optimizationR01HL151392 · NHLBI · CLEVELAND STATE UNIVERSITY · PI KOMAR, ANTON A. · 2020 to 2023
$1.5MNHLBI NIH HHS R01 HL151392
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Identifiers
PMID40413631
PMCPMC12578296
What OpenQuestion holds
Textmetadata
Read underepoch 390